Literature DB >> 7506195

Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils.

A J Verhoeven1, A T Tool, T W Kuijpers, D Roos.   

Abstract

In an inflammatory locus, products of activated neutrophils may be toxic both to the micro-organisms to be eliminated and to the surrounding tissue. In several models of inflammation, nimesulide possesses marked anti-inflammatory properties. The present study was undertaken to further investigate the effects of nimesulide on the activation of human neutrophils. Nimesulide caused a concentration-dependent inhibition of the homotypic aggregation of neutrophils upon activation with the receptor agonist formyl-Met-Leu-Phe. Likewise, nimesulide inhibited the heterotypic interaction of human neutrophils with endothelial cells in suspension. Since both these responses are mediated through activation of the integrin CD11b/CD18 on the neutrophil surface, we conclude that nimesulide interferes with the signal transduction leading to this activation. We also observed a strong inhibition of platelet-activating factor (PAF) synthesis by activated neutrophils in the presence of nimesulide. PAF has been implicated as an intercellular messenger in the diapedesis of neutrophils across endothelial cell monolayers after treatment with cytokines and in the activation of eosinophils.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506195     DOI: 10.2165/00003495-199300461-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  Inhibition of neutrophil oxidative metabolism by nimesulide.

Authors:  F Capsoni; E Venegoni; F Minonzio; A M Ongari; V Maresca; C Zanussi
Journal:  Agents Actions       Date:  1987-06

2.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Release of platelet-activating factor is important for the respiratory burst induced in human eosinophils by opsonized particles.

Authors:  A T Tool; L Koenderman; P T Kok; M Blom; D Roos; A J Verhoeven
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

Review 4.  The eosinophil and bronchial asthma: current understanding.

Authors:  G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1990-02       Impact factor: 10.793

Review 5.  Leukocyte-endothelial interactions.

Authors:  J M Harlan
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

6.  Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells.

Authors:  C Willems; G C Astaldi; P G De Groot; M C Janssen; M D Gonsalvez; W P Zeijlemaker; J A Van Mourik; W G Van Aken
Journal:  Exp Cell Res       Date:  1982-05       Impact factor: 3.905

7.  Role of endothelial leukocyte adhesion molecule-1 and platelet-activating factor in neutrophil adherence to IL-1-prestimulated endothelial cells. Endothelial leukocyte adhesion molecule-1-mediated CD18 activation.

Authors:  T W Kuijpers; B C Hakkert; M Hoogerwerf; J F Leeuwenberg; D Roos
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

8.  Continuous cell activation is necessary for stable interaction of complement receptor type 3 with its counter-structure in the aggregation response of human neutrophils.

Authors:  T W Kuypers; L Koenderman; R S Weening; A J Verhoeven; D Roos
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

9.  A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo.

Authors:  K E Arfors; C Lundberg; L Lindbom; K Lundberg; P G Beatty; J M Harlan
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

10.  A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.

Authors:  I Böttcher; A Schweizer; M Glatt; H Werner
Journal:  Drugs Exp Clin Res       Date:  1987
View more
  6 in total

1.  The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: anti-inflammatory effects of human PAF-acetylhydrolase.

Authors:  T W Kuijpers; J M van den Berg; A T Tool; D Roos
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

Review 2.  Nimesulide in dysmenorrhoea.

Authors:  M Pulkkinen
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 5.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

6.  Effects of nimesulide on kainate-induced in vitro oxidative damage in rat brain homogenates.

Authors:  Eduardo Candelario-Jalil; Olga Sonia León
Journal:  BMC Pharmacol       Date:  2003-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.